Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
The filing discloses a transaction involving Dr. P J T Vallance, a Person Discharging Managerial Responsibilities. On August 11, 2014, Dr. Vallance's spouse, Dr. S Dexter, purchased 7,225 Ordinary Shares of GSK at a price of 1,377.00 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total shareholding of Dr. P J T Vallance and connected persons following this purchase.
- Confirm the market price of GSK Ordinary Shares on August 11, 2014, to contextualize the 1,377.00 pence purchase price.
- Review subsequent filings to determine if this transaction was part of a broader insider trading pattern or a one-off event.